[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100558075":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":34,"responsibleParty":61,"collaborators":18,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":18,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":18,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":36,"whyStopped":18,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Women's Hospital School Of Medicine Zhejiang University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Femoston group","EXPERIMENTAL","Starting from the day of the induced abortion surgery, take 17β-estradiol\u002Fdydrogesterone tablets orally for 28 days (take 2mg of 17β-estradiol orally once a day for the first 14 days, and then take 2mg of 17β-estradiol + 10mg of dydrogesterone tablets orally once a day for the next 14 days).The medication product name is called Femoston。",[13],"Drug: 17β-estradiol\u002Fdydrogesterone tablets",{"label":15,"type":16,"description":17,"interventionNames":18},"No Femoston group","NO_INTERVENTION","The blank control group did not receive Femoston（17β-estradiol\u002Fdydrogesterone tablets after induced abortion surgery.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DRUG","17β-estradiol\u002Fdydrogesterone tablets","The medication group began taking 17β-estradiol\u002Fdydrogesterone tablets orally for 28 days starting from the first day after induced abortion surgery (taking 2mg of 17β-estradiol orally once a day for the first 14 days, and then taking 2mg of 17β-estradiol + 10mg of dydrogesterone tablets orally once a day for the next 14 days). The blank control group did not take any medication.",[9],[26],{"name":27,"affiliation":5,"role":28},"Xiuxiu Jiang, Ph.D","PRINCIPAL_INVESTIGATOR",[30],{"name":27,"role":31,"phone":32,"phoneExt":18,"email":33},"CONTACT","+8613588709941","jiangxiuxiu0418@zju.edu.cn",[35],{"facility":5,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"RECRUITING","Hangzhou","Zhejiang","310006","China","CN",{"type":43,"coordinates":44},"Point",[45,46],120.16142,30.29365,{"lat":46,"lon":45},[49,50,53,55,57,59],{"name":27,"role":31,"phone":32,"phoneExt":18,"email":33},{"name":51,"role":52,"phone":18,"phoneExt":18,"email":18},"Wanren Zheng, MD","SUB_INVESTIGATOR",{"name":54,"role":52,"phone":18,"phoneExt":18,"email":18},"Juan Yu, MD",{"name":56,"role":52,"phone":18,"phoneExt":18,"email":18},"Meijun Guo, MD",{"name":58,"role":52,"phone":18,"phoneExt":18,"email":18},"Ning Wang, MD",{"name":60,"role":52,"phone":18,"phoneExt":18,"email":18},"Shanshan Ni, MD",{"type":62,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100558075","phase-1-study-on-the-effect-of-combined-estrogen-and-progestogen-therapy-on-endometrial-repair-after-induced-abortion-100558075",false,"NCT06546397","Study on the Effect of Combined Estrogen and Progestogen Therapy on Endometrial Repair After Induced Abortion","Prospective Cohort Study on the Effect of Combined Estrogen and Progestogen Therapy on Endometrial Repair and Ovarian Function Recovery After Induced Abortion","Inclusion Criteria:\n\n* Age between 18 years old (inclusive) and 40 years old (inclusive)\n* Body Mass Index (BMI) ranging from 18.5Kg\u002F㎡ to 23.9Kg\u002F㎡\n* Experienced at least 2 abortions or had a missed abortion\n* Confirmed gestational age of no more than 10 weeks, and the ultrasonic examination within three days prior to the surgery shows a gestational sac (average of three diameters) of at least 1.0cm, with an embryo length of no more than 3.0cm\n* Normal preoperative examination results as per the \"Clinical Diagnosis and Treatment Guidelines and Technical Operation Standards: Family Planning Volume (2017 Revision)\"\n* Capable of regular follow-ups and willing to sign the informed consent form.\n\nExclusion Criteria:\n\n* Individuals with contraindications to estrogen and progesterone therapy\n* History of uterine adhesions confirmed by hysteroscopy, or a history of uterine cavity surgery or uterine malformation correction\n* Subjects who require placement of an intrauterine device or administration of oral contraceptives or subcutaneous implants after the procedure\n* Individuals with mental status or cognitive function abnormalities who are unable to cooperate with the treatment process\n* Subjects who, in the opinion of the investigator, have potential risks or any other factors that may interfere with the study.","FEMALE","18 Years","40 Years",{"count":74,"type":75},200,"ESTIMATED","INTERVENTIONAL",[78],"PHASE1","Induced abortion is a common method to terminate pregnancy, but during the operation, it is necessary to dilate the cervix and aspirate the uterine cavity. Repeated induced abortions may increase the risk of uterine damage, leading to cervical stenosis or intrauterine adhesions, thinning of the endometrium, which may affect the implantation of fertilized eggs and the development of embryos, and ultimately may lead to infertility or miscarriage. This study aims to explore the effects of combined estrogen and progesterone on endometrial repair and ovarian function recovery after induced abortion.",[81],"Pregnancy Complications",[83,84,85,86],"induced abortion","Intrauterine adhesion","estrogen","endometrial repair","2025-08-20",{"date":89,"type":90},"2025-08-28","ACTUAL",{"date":92,"type":90},"2024-05-09",{"date":94,"type":75},"2025-12-31",{"name":5,"class":6},1]